Patent application number | Description | Published |
20080311190 | Thrombin-Free Biological Adhesive and Use Thereof as a Medicament - The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor VIIa and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials. | 12-18-2008 |
20090074749 | IMMUNOGLOBULIN G (IgG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES AND OF POLYREACTIVE IgGs - The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG. | 03-19-2009 |
20090317373 | Inhibition of the Anti-FVIII Immune Response - The invention relates to a compound capable of inhibiting the endocytosis of FVIII (factor VIII) by immune system cells capable of endocytosing the antigen and to the therapeutic use of such a compound for the manufacture of a medicament for use in the treatment of hemophiliacs in order to reduce the immunogenicity of FVIII and/or increase the half-life of FVIII. | 12-24-2009 |
20110097715 | METHOD FOR PURIFYING OR DETECTING A TARGET PROTEIN - A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution. | 04-28-2011 |
20130149292 | THROMBIN-FREE BIOLOGICAL ADHESIVE AND USE THEREOF AS A MEDICAMENT - The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials. | 06-13-2013 |
20140141021 | METHOD FOR PREPARING A CONCENTRATE OF POLYVALENT IMMUNOGLOBULIN - The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained. | 05-22-2014 |
Patent application number | Description | Published |
20090239788 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others. | 09-24-2009 |
20090311239 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of GalĪ±1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII | 12-17-2009 |
20100197578 | DEMANNOSYLATED RECOMBINANT FACTOR VIII [[VII]] FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A - There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies. | 08-05-2010 |
20130189244 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others. | 07-25-2013 |
20140093491 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS - The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of GalĪ±1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII. | 04-03-2014 |
Patent application number | Description | Published |
20110162094 | MODIFIED HUMAN FACTOR VII/VIIA AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Modified factors VII/VIIa with a high stability, nucleic acids encoding such modified factors VII/VIIa, and methods of preparing the same. | 06-30-2011 |
20130143302 | METHOD FOR PURIFYING GLA-DOMAIN COAGULATION PROTEINS - A method for purifying GLA-domain coagulation proteins, includes the following steps: a) bringing a sample containing one or more GLA-domain coagulation proteins into contact with an affinity substrate on which nucleic aptamers which bind specifically to the GLA-domain coagulation proteins are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the GLA-domain coagulation protein(s) in a purified form. | 06-06-2013 |
20130202585 | STABILISING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND IN LYOPHILISED FORM - This invention is related to a stabilising formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilisation of immunoglobulins G compositions in liquid form and in lyophilised form. The invention also relates to an immunoglobulins G composition in liquid form or in lyophilised form comprising said stabilising formulation. | 08-08-2013 |
20130324619 | GLYCOLS AS PATHOGEN INACTIVATING AGENTS - The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent. | 12-05-2013 |